These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15723619)

  • 21. Future directions in the treatment of androgen-independent prostate cancer.
    Petrylak DP
    Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combinatorial androgen receptor targeted therapy for prostate cancer.
    Singh P; Uzgare A; Litvinov I; Denmeade SR; Isaacs JT
    Endocr Relat Cancer; 2006 Sep; 13(3):653-66. PubMed ID: 16954423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of prostate cancer. Part 3: metastatic disease.
    Shah J; Khaksar SJ; Sooriakumaran P
    Expert Rev Anticancer Ther; 2006 May; 6(5):813-21. PubMed ID: 16759171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
    Rahman KM; Banerjee S; Ali S; Ahmad A; Wang Z; Kong D; Sakr WA
    Cancer Res; 2009 May; 69(10):4468-75. PubMed ID: 19435906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
    Sava T; Basso U; Porcaro A; Cetto GL
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiogenesis as a strategic target for prostate cancer therapy.
    Li Y; Cozzi PJ
    Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiogenesis-targeted therapies in prostate cancer.
    Lara PN; Twardowski P; Quinn DI
    Clin Prostate Cancer; 2004 Dec; 3(3):165-73. PubMed ID: 15636683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer.
    Shabbir M; Ryten M; Thompson C; Mikhailidis D; Burnstock G
    BJU Int; 2008 Feb; 101(3):352-9. PubMed ID: 18005209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer: horizons in the development of novel anti-cancer strategies.
    Papatsoris AG; Papavassiliou AG
    Curr Med Chem Anticancer Agents; 2001 May; 1(1):47-70. PubMed ID: 12678770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Future therapies in hormone-refractory prostate cancer.
    Smith MR; Nelson JB
    Urology; 2005 May; 65(5 Suppl):9-16; discussion 17. PubMed ID: 15885273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?
    Cella D; Petrylak DP; Fishman M; Teigland C; Young J; Mulani P
    Eur Urol; 2006 May; 49(5):781-9. PubMed ID: 16458417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Targeted therapies for hormone-refractory prostate cancer].
    Song HZ; Chen LB
    Zhonghua Nan Ke Xue; 2010 Dec; 16(12):1108-12. PubMed ID: 21348204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapy of hormone refractory prostate cancer: new standards, new trends].
    Wülfing C; Bierer S; Bögemann M; Piechota H; Hertle L
    Aktuelle Urol; 2005 Aug; 36(4):342-8. PubMed ID: 16110408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer.
    Miyoshi Y; Ishiguro H; Uemura H; Fujinami K; Miyamoto H; Miyoshi Y; Kitamura H; Kubota Y
    Prostate; 2003 Sep; 56(4):280-6. PubMed ID: 12858356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New approaches in hormone refractory prostate cancer.
    Sonpavde G; Hutson TE
    Am J Clin Oncol; 2006 Apr; 29(2):196-201. PubMed ID: 16601442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy.
    Yoshino T; Shiina H; Urakami S; Kikuno N; Yoneda T; Shigeno K; Igawa M
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6116-24. PubMed ID: 17062688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the relaxin hormonal pathway in prostate cancer.
    Neschadim A; Summerlee AJ; Silvertown JD
    Int J Cancer; 2015 Nov; 137(10):2287-95. PubMed ID: 25043063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005?
    Strother JM; Beer TM; Dreicer R
    Eur J Cancer; 2005 Apr; 41(6):954-64. PubMed ID: 15808961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell signaling modifiers in prostate cancer.
    Chen FL; Armstrong AJ; George DJ
    Cancer J; 2008; 14(1):40-5. PubMed ID: 18303482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.